|
Market Report
|
Gastric Cancer - Targeted therapies compete for first-to-market status
Gastric cancer incidence in 2009 is forecast to be 197,000 in the seven major pharmaceutical markets (US, Japan, Germany, France, Italy, Spain, and UK). Although, the global incidence has decreased in recent years, mortality remains high, particularly in the US and Europe. Therefore, predictably a high unmet need remains for effective therapies to improve mortality.
|
|
Read more...
|
|
|
Market Report
|
Pharmaceuticals: Global Industry Almanac
Datamonitor's Pharmaceuticals: Extended Global Industry Guide is an essential resource for top-level data and analysis covering the Pharmaceuticals industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis on a global, regional and country basis.
|
|
Read more...
|
|
|
Market Report
|
Schizophrenia - Second generation depots protect market value
Schizophrenia is a chronic and severe mental health disorder affecting around 4.6 million schizophrenia sufferers across the seven major markets. Currently led by oral branded atypical antipsychotics, the schizophrenia market will undergo some big changes over the period 2008/2017. Prospective players can expect to face stiff competition from generic versions of all currently branded drugs.
|
|
Read more...
|
|
|
Market Report
|
Commercial dynamics and outlook of the neurology, pain and psychiatry market sectors
The market for CNS drugs across the 7MM was worth a substantial $95.5 billion, accounting for a 21.4% share of the total pharmaceutical market value in 2007. Despite stalling R&D productivity and the genericization of the majority of leading CNS blockbuster brands, the market continues to offer a wealth of lucrative opportunities for all types of drug manufacturer.
|
|
Read more...
|
|
|
Market Report
|
Pricing and Reimbursement in The United Arab Emirates
The healthcare sector in the emirates of Abu Dhabi and Dubai is undergoing drastic changes as a result of the structural and financing reforms that will impact all major actors in the healthcare sector.
|
|
Read more...
|
|
|
Market Report
|
Future Pharmaceutical Industry Trends: Long-term opportunities tempered by short-term challenges
In recent years, Pharma has begun to adapt its business model in response to growing industry constraints and the decline of the primary-care focused blockbuster therapy. This process of change has recently been disrupted by unprecedented challenges caused by the global economic downturn, and by President Obama's planned overhaul of the US healthcare system.
|
|
Read more...
|
|
|
Market Report
|
Generic Benchmarking: Brand Erosion at Patent Expiry
Not only is Pharma facing a continued slow down in sales growth in the seven major markets, but erosion of branded drugs by generics follow patent expiry is increasing, driven by evolving payer initiatives to incentivize generic use.
|
|
Read more...
|
|
|
Market Report
|
Tuberculosis - Development pipeline shows signs of life
Tuberculosis is a major cause of illness and death worldwide, but despite 14.4 million prevalent cases, 9.2 million new cases and 1.7 million deaths in 2006, the small and rapidly declining burden of disease in the seven major markets has limited drug and vaccine development activities until recently.
|
|
Read more...
|
|
|
Market Report
|
Healthcare Technology Opportunities in the Electronic Health Record Market (Review Report)
Electronic health records (EHRs) will be the cornerstone of healthcare technology. The design, selection and implementation of EHRs, therefore, will be extremely important for healthcare institutions.
|
|
Read more...
|
|
|
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
|
| Results 73 - 81 of 324 |
Farmavita.Net Journal 
